News
Agenus (AGEN) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
Agenus (NASDAQ: AGEN)Q4 2023 Earnings CallMar 14, 2024, 8:30 a.m. ET
Operator
Source Fool.com
EQS-News: Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
Is Viatris a Great Dividend Stock or Just a Value Trap?
Viatris (NASDAQ: VTRS) is a large and diverse pharmaceutical business that spun off from Pfizer in 2020. The company's medications are in 165 countries and much of its business centers around
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling?
Sarepta Therapeutics (NASDAQ: SRPT) could have a serious new competitor on the horizon. According to some fresh clinical data from Regenxbio (NASDAQ: RGNX), another biotech, the company is making
Could Viking Therapeutics Challenge Giant Eli Lilly in the Billion-Dollar Weight-Loss Drug Market?
Viking Therapeutics (NASDAQ: VKTX) shares soared more than 120% in one trading session last month as investors bet on its ability to win in the billion-dollar weight-loss drug market -- or attract a
CorMedix (CRMD) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
CorMedix (NASDAQ: CRMD)Q4 2023 Earnings CallMar 12, 2024, 8:30 a.m. ET
Operator
Source Fool.com
Is Nvidia Stock a Buy?
Nvidia (NASDAQ: NVDA) won over Wall Street last year, illustrated by its more than 280% stock growth since March 2023. The company's years of dominance in graphics processing units (GPUs) perfectly
Why Cathie Wood Thinks Bitcoin Could Soar to More Than $1 Million Before 2030
In an interview on the New Zealand Herald's Markets With Madison online video show, Cathie Wood once again reiterated her belief that Bitcoin (CRYPTO: BTC) will soar to more than $1 million sooner
GenSight Biologics Announces Initial Results from New Meta-Analyses on Visual Outcomes with LUMEVOQ® Gene Therapy at NANOS 2024
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311531952/en/
Figure 1. Visual Recovery (CRR from Nadir) Among
2 Dirt Cheap Dividend Stocks to Buy and Hold
Dividend stocks are great for several reasons. Some use the regular payouts they offer to complement their income, whether in retirement or otherwise, while others reinvest the money to boost
3 Pharmaceutical Stocks to Buy Hand Over Fist in March
Pharmaceutical companies play a tremendous role in modern healthcare. While sometimes controversial, drugmakers design medicine to treat some of the worst ailments plaguing society and constantly
Is Viking Therapeutics Stock a Buy?
With Viking Therapeutics (NASDAQ: VKTX) stock exploding skyward by 528% over the last 12 months, it's easy to wonder if the opportunity to buy its stock is too good to be true -- and a bit too late.
1 Small Semiconductor Stock Up 50% in 2024 Alone -- Is It Too Late to Buy?
2024 has gotten off to quite the start. As investors warm up to the idea that a new bull market has begun, interest has flooded into the semiconductor industry, with names like Nvidia and Advanced
Have $2,000? 2 Magnificent Stocks Ready for a Bull Run
Stocks across a range of industries and sectors have dealt with unique challenges over the last few years. While some companies are still dealing with the effects of a slowdown in growth following
3 Dividend Stocks to Buy Hand Over Fist in March
Get paid to own a stock whether it moves higher or lower. What a concept! And it's one that any investor who buys dividend stocks can enjoy. Three Motley Fool contributors believe they've identified
Is Intellia Therapeutics Stock a Buy Now?
Many investors were skeptical of biotechs specializing in gene editing three years ago. Though some had made clinical progress, few had launched any product. Since then, there have been more
Have $2,500? 2 Superior Growth Stocks to Buy in 2024
Stocks have been off to a very bullish start in 2024, and investors seem increasingly optimistic about the overall state of the market and the global economy. Now, that's not to say there aren't
2 Biotech Stocks to Buy Hand Over Fist in March
Could this be the year biotech stocks bounce back? The industry has been in a slump over the past couple of years, but it started 2024 with a bang. The SPDR S&P Biotech ETF, which tracks an industry
MacroGenics (MGNX) Q4 2023 Earnings Call Transcript
Image source: The Motley Fool.
MacroGenics (NASDAQ: MGNX)Q4 2023 Earnings CallMar 07, 2024, 4:30 p.m. ET
Operator
Source Fool.com
EQS-News: Invitation to MorphoSys’ Full Year Results 2023 Conference Call on March 14, 2024
Why Viking Therapeutics Stock Is Plunging Today
Shares of Viking Therapeutics (NASDAQ: VKTX) were plunging 17.4% lower as of 11:52 a.m. ET on Thursday. This decline wasn't caused by an announcement by Viking. Instead, the sell-off appears to be
Recursion Pharmaceuticals Stock Has 33% Upside, According to 1 Wall Street Analyst
On Monday, Keybanc analyst Scott Schoenhaus revised his price target on Recursion Pharmaceuticals (NASDAQ: RXRX) upward, opining the stock would climb by 33% and hit $16. The call came days after
1 Wall Street Analyst Thinks Pfizer Stock Is Going to $45. Is It a Buy Around $26?
Per Cantor Fitzgerald analyst Louise Chen's calculations published March 4, Pfizer's (NYSE: PFE) stock is going to climb by around 75% to reach or surpass $45 over the coming quarters. Chen's
Buy This Beaten-Down High-Yield Dividend Stock Before It's Too Late
The stock market has slowly started to come to its senses about telecom giant AT&T (NYSE: T). While the stock is still down significantly from its all-time high, shares have surged around 25% since